Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HZBio2 vs vedolizumab in moderate to severe active ulcerative colitis (China, phase 3)
CTR20252645Phase 3Active
- Sponsor
- Hangzhou Grand Biologic Pharmaceutical Inc.
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of HZBio2 in autoimmune colitis, sponsored by Hangzhou Grand Biologic Pharmaceutical Inc.. Started Aug 2025; status: active.
02
Drugs
HZBio2
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20252645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252645.